Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-06-01 Calcitonin and parathyroid hormone
| Abaloparatide |
|
Formulary
|
Osteoporosis after menopause. |
 NICE TA991: Abaloparatide for treating osteoporosis after menopause |
|
| Teriparatide |
|
Formulary
|
Injection 750micrograms/3mL prefilled pen For specialist use only in accordance with NICE TA guidance (women) or NHS England commissioning policy (men).
|
 NHSE: Clinical Commissioning Policy: Teriparatide for Osteoporosis in Men (Adults) NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
|
|
Links
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- NHSE: Clinical Commissioning Policy: Teriparatide for Osteoporosis in Men (Adults)
- NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA625: Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)
- NICE TA991: Abaloparatide for treating osteoporosis after menopause
- Osteoporosis Guideline (NOGG 2021)